Clarivate (CLVT) plans potential NYSE sale of ProQuest merger consideration shares

Rhea-AI Filing Summary

Clarivate plc is the issuer in a notice covering potential sales of its ordinary shares under a Form 144 filing. The planned transactions are to be executed through J.P. Morgan Securities LLC on the NYSE.

The shares were originally acquired on December 1, 2021 as consideration in connection with the merger of ProQuest LLC into Clarivate. The filing references 2,489,618 ordinary shares tied to that merger consideration, indicating these previously issued shares may be sold in the market.

Key Figures

Shares linked to merger consideration: 2,489,618 ordinary shares Acquisition date of shares: 12/01/2021 Trading venue: NYSE

3 metrics

Shares linked to merger consideration 2,489,618 ordinary shares Referenced as consideration in connection with the merger of ProQuest LLC into Clarivate on 12/01/2021

Acquisition date of shares 12/01/2021 Date the ordinary shares were received as merger consideration

Trading venue NYSE Exchange where the ordinary shares covered by the Form 144 may be sold

Key Terms

Form 144, Ordinary Shares, consideration, merger

4 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Ordinary Shares financial

"Ordinary Shares | J.P. Morgan Securities LLC 270 Park Avenue"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

consideration financial

"As consideration in connection with the merger of ProQuest LLC"

merger financial

"in connection with the merger of ProQuest LLC into Clarivate"

A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 07:18 PM Accepted by SEC EDGAR 08/03/2026 - 07:17 PM Learn about SEC filing dates

FAQ

What does Clarivate (CLVT) disclose in this Form 144 filing?

Clarivate discloses a planned sale program for ordinary shares previously issued as merger consideration for ProQuest LLC, to be sold through J.P. Morgan Securities LLC on the NYSE.

How many Clarivate (CLVT) shares are linked to the ProQuest merger in this filing?

The filing references 2,489,618 ordinary shares acquired on December 1, 2021 as consideration in connection with the merger of ProQuest LLC into Clarivate.

When were the Clarivate (CLVT) shares proposed for sale originally acquired?

The shares were acquired on December 1, 2021 as consideration in the merger of ProQuest LLC into Clarivate, meaning they represent stock issued in exchange for that transaction.

Through which broker will the Clarivate (CLVT) shares in this Form 144 be sold?

The proposed sales are to be executed through J.P. Morgan Securities LLC, located at 270 Park Avenue, New York, with the shares to be traded on the NYSE.

What type of Clarivate (CLVT) security is involved in this Form 144 notice?

The notice covers ordinary shares of Clarivate, linked to 2,489,618 shares received as merger consideration for ProQuest LLC and potentially sold on the NYSE.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	J.P. Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	2489618	4929444	639664003	08/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	12/01/2021	As consideration in connection with the merger of ProQuest LLC into Clarivate	Issuer			2489618	12/01/2021	Consideration

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)